Insider Trading July 14, 2026 08:10 PM

Liquidia CFO Jason Adair Executes $562K Share Sale Under Pre-Arranged Plan

Executive divestment coincides with broader analyst adjustments and index inclusion for the pharmaceutical firm.

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
LQDA

Liquidia Corp (NASDAQ:LQDA) Chief Business Officer Jason Adair executed a sale of 7,863 shares on July 13, 2026, realizing $562,288. The transaction was facilitated through a Rule 10b5-1 trading plan established in December 2023, primarily intended to cover tax liabilities from the settlement of restricted stock units (RSUs) and performance stock units (PSUs). This sale follows a prior acquisition of 10,251 shares on July 10, 2026, through equity settlement. The company has recently been included in the S&P SmallCap 600 Index, and analyst ratings from BofA Securities, H.C. Wainwright, and Raymond James reflect mixed perspectives on its valuation and legal outlook.

Liquidia CFO Jason Adair Executes $562K Share Sale Under Pre-Arranged Plan
LQDA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Executive divestment: Jason Adair sold $562,288 worth of shares under a Rule 10b5-1 plan to cover tax liabilities from RSU and PSU settlements.
  • Market performance: Liquidia stock has surged 427% over the past year, reaching $76.47, though some models suggest it may still be undervalued.
  • Analyst divergence: BofA Securities downgraded to Neutral with a $79 target, while H.C. Wainwright and Raymond James maintained Buy ratings with targets of $75 and $68 respectively, citing legal developments.

Jason Adair, serving as the Chief Business Officer for Liquidia Corp (NASDAQ:LQDA), executed a transaction involving the sale of 7,863 shares of common stock on July 13, 2026. The aggregate value realized from this divestment stood at $562,288. The execution price for these shares ranged between $71.39 and $71.52. The transaction was conducted under the parameters of a Rule 10b5-1 trading plan, a mechanism designed to facilitate pre-arranged sales, which Mr. Adair initially adopted on December 15, 2023. The primary motivation cited for this specific sale was to cover tax obligations associated with the settlement of restricted stock units (RSUs) and performance stock units (PSUs).

The sale occurred against a backdrop of significant price appreciation for Liquidia. The stock had recently climbed to $76.47, marking a substantial 427% return over the preceding twelve-month period. Market analysis from InvestingPro suggests that despite this surge, Liquidia may currently be trading below its estimated fair value, presenting a potential valuation discrepancy according to their models.

Prior to the divestment, Mr. Adair had acquired a substantial block of 10,251 shares on July 10, 2026. This acquisition was not a market purchase but rather the result of equity settlement. The shares were obtained at a price of $0.0 per share, converting on a one-for-one basis from RSUs and PSUs. The breakdown of this acquisition includes 3,907 shares from RSUs granted on January 11, 2023, 2,475 shares from PSUs granted on January 11, 2024, and 3,869 shares from PSUs granted on January 11, 2025.

Following these recent transactions, Mr. Adair's direct holdings in Liquidia Corp common stock total 217,126 shares. This balance sheet position includes a variety of unvested equity awards that have not yet converted to common stock. Specifically, he holds 7,812 unvested RSUs from a July 6, 2023 grant, 14,845 unvested RSUs from a January 11, 2024 grant, and 38,684 unvested PSUs from a January 11, 2025 grant. Additionally, he retains 27,683 unvested RSUs from a January 16, 2026 grant and 12,023 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.

Corporate developments for Liquidia extend beyond executive transactions. The company announced its inclusion in the S&P SmallCap 600 Index, effective June 22. This index tracks 600 U.S. small-cap companies based on market capitalization and other specific criteria, signaling a shift in the company's market classification.

Analyst sentiment regarding Liquidia shows divergence. BofA Securities downgraded the stock rating from Buy to Neutral, citing a balanced risk-reward profile following recent gains, though they raised the price target to $79. H.C. Wainwright adjusted its price target to $75 while maintaining a Buy rating, influenced by a Supreme Court ruling that may benefit Liquidia's ongoing legal case. Raymond James reiterated a Strong Buy rating with a $68 price target, also highlighting positive implications from the same Supreme Court decision involving Hikma Pharmaceuticals and Amarin.

Risks

  • Valuation volatility: The stock's 427% annual return raises questions about sustainability, with some analysts noting a balanced risk-reward profile.
  • Legal dependency: Analyst price targets are influenced by a Supreme Court ruling involving Hikma Pharmaceuticals and Amarin, indicating potential legal risk exposure.
  • Index inclusion impact: The move to the S&P SmallCap 600 Index may alter liquidity and institutional ownership dynamics, though specific impacts are not detailed.

More from Insider Trading

Broadcom's Chief Legal Officer Executes $10 Million Share Sale Amid Strategic Expansions Jul 14, 2026 Liquidia Corp CHRO Sarah Krepp Offloads Shares Under Pre-Arranged Plan Jul 14, 2026 Liquidia Corp CDO Khindri Executes $84,740 Stock Sale Under Pre-Arranged Plan Jul 14, 2026 Liquidia CFO Michael Kaseta Offloads Over $1.46M in Shares Amid Stock Surge Jul 14, 2026 Liquidia General Counsel Executes $1.05 Million Stock Sale Under Pre-Existing Plan Jul 14, 2026